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Abstract 
Aims  
We aimed to assess the incidence and baseline characteristics of first ever 
intracerebral hemorrhage (ICH) in Southern Norway leading to hospitalization, 
mortality rates after ICH and factors associated with 30-day mortality and long term 
mortality. We further aimed to assess clinical functioning including cognition in long 
term survivors and associations between baseline factors and 1) functional 
dependency and 2) cognitive impairment. We also aimed to assess the rate of 
recurrent ICH and late seizures. 
Materials and methods  
All consecutive patients hospitalized with a first-ever ICH in the period 2005-2009 in 
a well-defined area were identified. Risk factors, clinical-, and radiological data were 
recorded in a stroke register from September 2007 and retrieved from patient files in 
cases prior to that. In Paper I we calculated the crude incidence and the incidence 
adjusted to the standard European population. In paper II death registered up to 
December 31.2011 in the National Population Register was recorded and causes of 
death were obtained from Statistics Norway and patient files. The prognostic value of 
various baseline clinical and radiologic factors for 30-day and long term mortality 
was assessed. Information on recurrent ICH was obtained by review of patient files. 
In Paper III we did an extensive in person follow up of all long term survivors 
between August and November 2011. This included the National Institute of Health 
Stroke Scale (NIHSS), the modified Rankin Scale (mRS), the Barthel Index (BI) and 
the Montreal Cognitive Assessment (MoCA). Information on late seizures was 
obtained through the in person follow up and by review of patient files. 
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Results 
Incidence (Paper I) 
We identified 134 patients, 74 (55%) men and 60 (45%) women with first ever ICH. 
The crude annual incidence rate per 100.000 per year was 19.6 for men, 15.7 for 
women and 17.6 for both sexes.  Adjusted to the standard European population it was 
16.9 for men, 8.8 for women (p<0.001) and 12.5 for both sexes. The overall age 
adjusted rate ratio men/women was 1.78 (p=0.001). Hematoma location was lobar in 
36.6%, deep cerebral in 45.5%, cerebellar in 9.7%, and brain stem in 8.2%.  
Intraventricular hemorrhage occurred in 37%. The proportion with oral anticoagulant 
treatment associated ICH (OAT-ICH) was 26.9%.  
Mortality (Paper I and II) 
Overall mortality at 2 days was 23%, at 7 days 30%, at 30 days 36.6%, at 1 year 46 % 
and at 2 years 53%. Factors independently associated with 30-day mortality were 
warfarin, Glasgow Coma Scale (GCS) score, intraventricular hemorrhage, and 
leukoaraiosis (LA) score. Factors independently associated with long term mortality 
in 30-day survivors were coronary heart disease (CHD), GCS score, and LA score. 
Median follow up time was 4.7 years. 
Recurrent ICH (Paper II) 
Recurrent ICH was seen in 4 of 36 patients (11.1%) discharged alive after a lobar 
index ICH versus 0 of 52 (0%) after index ICH in other locations (p=0.025).  
Clinical functioning in long term survivors (Paper III) 
Of 51 patients alive 50 (24 men and 26 women) had an in person follow up after a 
median of 3.8 years. Men were younger than women (70.4 versus 78.7 years, 
p=0.019). Forty one (82%) lived in their private homes and 9 (18%) in nursing 
homes, 34 (68%) were independent (mRS 0-2) and 16 (32%) were dependent (mRS 
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3-5). Factors independently associated with dependency were female sex and LA 
score. 
The proportion with cognitive impairment (MoCA≤23) was 61.4%. Factors 
independently associated with cognitive impairment were age and lobar ICH location.  
Late seizures (not published) 
Late seizures occurred in 5 of 50 (10%) long term survivors; 5 of 19 (26%) with lobar 
ICH versus 0 of 31 (0%) with ICH in other locations (p=0.005). Patients with late 
seizures had larger median ICH volumes than patients without seizures, 39 ml (IQR 
23.5- 58.5) versus 7 ml (IQR 2.5-16.5), p=0.004.  
Conclusions 
The incidence of first ever ICH in Southern Norway is in the mid range in Europe and 
lower than in the only prior Norwegian incidence study.  Men are at higher risk than 
women.  
The proportion with OAT-ICH is higher than in most reports reflecting a well 
implemented use of warfarin in atrial fibrillation in the elderly (Paper I). 
LA is independently associated with both 30-day mortality and long term mortality in 
30-day survivors. Warfarin is independently associated with 30-day mortality and 
coronary heart disease with long term mortality in 30-day survivors. Recurrent ICH is 
more frequent after lobar ICH than after ICH in other locations (Paper II). 
The majority of long term survivors live in their private homes. Two thirds are 
functionally independent. Dependency is associated with LA and female sex. 
Cognitive impairment is common and associated with lobar location of ICH (Paper 
III). 
Late seizures were associated with lobar index ICH and larger ICH volumes (not 
published).  
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1. Background 
Intracerebral hemorrhage (ICH) is a significant cause of morbidity and mortality 
throughout the world [1]. It is the most serious type of stroke and accounts for 10-
15% of all strokes in Western countries [2-5].  Mortality is higher than in ischemic 
stroke with 35–52% of patients dead within 1 month.   
1.1 Intracerebral Hemorrhage - definition 
ICH is defined as the abrupt onset of severe headache, altered level of consciousness, 
or focal neurological deficit associated with a focal collection of blood within the 
brain parenchyma on neuroimaging or at autopsy which is not due to trauma or 
hemorrhagic conversion of a cerebral infarction [6]. The international classification 
of disease (ICD) uses the diagnosis “nontraumatic ICH” in both ICD 9 (code 431) 
and ICD 10 (codes I 61.0-9) [7] . The updated American Heart Association 
(AHA)/American Stroke association (ASA) definition of stroke (2013) uses  the term 
“Intracerebral Hemorrhage” with the criterion non traumatic incorporated  in this 
term [8].   
In the literature the terms “spontaneous ICH” and  ”primary ICH” are often used.  
Neither is clearly defined or consistently used. Neither is used in ICD 10 or the 
updated AHA/ASA definition [7, 8]. Exclusion criteria vary between publications. 
Most consistently excluded are, hemorrhages related to intracerebral malignant 
tumors, surgery and aneurysms. Patients with oral anticoagulant treatment (OAT) are 
often included and patients with vascular malformation are to a various degree 
excluded. The inconsistent use of the term “Primary ICH” is illustrated in a review of 
population based studies of ICH in which a web appendix reveals interchangeable use 
of terms, highly varying definitions and frequently “no definition” [9].    
 
“
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1.2 Incidence of  Intracerebral Hemorrhage 
In a recent European multi-population study the annual incidence of ICH per 100,000 
adjusted to the standard European population was 16.9 in men and 12.4 in women in 
2004–2006, but there was considerable variation between different European regions 
[10]. In Italy in 1994–1998 a crude annual incidence rate for a first-ever ICH was 
36.9 per 100,000. When standardized to the 2006 European population it was 32.9 
per 100,000 [11].  
Stroke incidence has decreased by 42% in the past four decades in high-income 
countries. This is driven by a reduction in incidence of ischemic stroke [12]. Whether 
incidence of ICH has also fallen is unclear. In a recent review of population based 
studies there was no substantial decrease in incidence over time when only studies 
with excellent case-finding and no age limit were included [9].  
Incidence – need for new data 
Norwegian data on the incidence of ICH prior to the current study are limited to one 
study of stroke epidemiology in mid-Norway in 1994–1996 with only 45 cases of 
ICH. The crude annual incidence was 32 per 100,000. Sex distribution and 
adjustment to the standard European population were not reported, nor imaging 
findings such as ICH location and volume [13].   
Therefore there was a need for new Norwegian incidence data with age and sex 
distribution, adjustment to the standard European population, and details on ICH 
locations and volume, rate of intraventricular hemorrhage and rate of oral 
anticoagulant treatment (OAT). 
1.3 ICH Locations  
Bleeding often occurs in the cerebral lobes, basal ganglia, thalamus, brain stem 
(predominantly the pons) and cerebellum [14, 15]. In studies of epidemiology and 
prognosis, ICH is frequently divided into subtypes by location. The origin of the 
bleeding is sought on computed tomography (CT), magnetic resonance imaging 
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(MRI) or autopsy. A classification with four categories is often used;  lobar (cortical 
or subcortical white matter), deep cerebral (periventricular white matter, basal 
ganglia, internal capsule, thalamus), brain stem (midbrain, pons, medulla) and 
cerebellar ICH [16]. This classification is used in the present study.  
Extension into the ventricles is common. It has been reported in 36-42 % of cases 
[17-19], and is found particularly in large deep hemorrhages [20] .  
1.4 Causes of ICH 
ICH is bleeding into the brain parenchyma.  Most cases are caused by spontaneous 
rupture of small vessels affected by hypertension-related degenerative changes or 
cerebral amyloid angiopathy. Other more rare causes include vascular malformations 
and impaired coagulation [14].   In patients younger than 40 years vascular 
malformations are the most common single cause of ICH [21]. 
1.5 Evolution of hematoma 
Hematoma growth 
ICH is a dynamic process. Ongoing hematoma growth at the time of admission to 
hospital is common. This was first reported in the 1990`s [22, 23].  The most 
common definitions are a proportional increase of ICH volume on CT (>33%) or an 
absolute increase (typically 3, 6 or 12 ml) or a combination of both [24, 25]. Since 
hematoma growth is most common in the first hours, the delay from symptom onset 
to first imaging influences the observed proportion with hematoma growth. In a study 
of 218 patients who had a CT within 3 hours of symptom onset and a 24 hour control 
CT, some degree of hematoma expansion was seen in 73% and significant (>33%) 
expansion in approximately one third of the patients [26]. Hematoma growth is 
directly associated with clinical deterioration and poor outcome [22, 23, 26, 27].  
Risk factors for hematoma growth include the initial ICH volume: larger hematomas 
are more likely to expand [28, 29]  and OAT [30, 31] . The possession of an APOE ε2 
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allele is also associated with increased risk of hematoma growth in lobar ICH [32].  A 
recent study of 79 patients in the US showed an association between LA and greater 
ICH volumes and a trend towards more hematoma growth [33]. 
The avalanche model   
Hematoma expansion is often explained as continuous bleeding from a single vessel 
that bursts. In the early 1970`s Dr. Miller Fisher proposed an alternative “avalanche 
model” in which the ICH spreads in a domino fashion in the cerebral parenchyma.  
He observed multiple recently ruptured vessels at the periphery of hematomas and 
suggested that expansion of the initial hematoma caused secondary mechanical 
shearing of neighboring vessels  [34].  In a recent review the authors state that several 
recent observations support the “avalanche model”  including the common finding of 
multiple spot signs (see next paragraph) within a single hematoma indicating multiple 
bleeding sites [35, 36].   
Extravasation of contrast  –  the Spot Sign  
The spot sign was first reported in 2007 and has since that been extensively studied.  
It is the appearance of contrast extravasation into the hematoma on CT. It is a strong 
predictor of hematoma expansion, poor functional outcome and death [36-39].  
Multiple spot signs are often found and it has been shown that the number of spot 
signs is predictive for hematoma expansion [36, 40]. 
The presence of contrast extravasation on MRI was also shown to be  closely 
correlated with hematoma enlargement on follow-up CT scans in 1998, but has since 
been far less studied than the CTA spot sign [41]. 
 
 16 
1.6  Risk factors for Intracerebral Hemorrhage 
1.6.1 Sex and Age 
The risk of ICH is associated with increasing age and male sex. In a systematic 
review of case control and cohort studies the relative risk for ICH increased nearly 2-
fold per decade. The crude relative risk for men compared with women was 3.3-4.3 
[42] . 
1.6.2 Hypertension 
Hypertension is the most important risk factor for ICH [14].  In a systematic review 
of 11 case control studies all studies showed a positive association between 
hypertension and the risk of ICH. The overall odds ratio was 3.7 [42]. Hypertension 
is more common in deep cerebral than in lobar ICH [43, 44]. In hypertension related 
ICH it has been demonstrated, in histopathology studies, that the site of rupture 
typically is at or near a vessel bifurcation. The vessels show severe degeneration with  
breakage of the lamina elastica, atrophy and fragmentation of smooth muscle and 
dissections  [45] .   
1.6.3 Cerebral amyloid angiopathy 
Cerebral amyloid angiopathy (CAA) is a common small vessel disease of the brain, 
characterized by the progressive deposition of amyloid b protein in the walls of small 
to medium sized arteries.  It favors cortical regions.  CAA is associated with 
increased risk of ICH, particularly lobar [46]. There is evidence of CAA as an 
important underlying cause of OAT-ICH. In patients with CAA transient focal 
neurological episodes interpreted as TIA`s often prove to be small hemorrhages 
which may carry a high risk of future symptomatic hemorrhages [47]. CAA is 
associated with cognitive impairment.  Population based autopsy studies indicate a 
prevalence of 20-40% in non demented, 50-60% in demented elderly and more than 
90% in persons with Alzheimer’s disease [46]. 
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The gold standard for diagnosing CAA is a neuropathological examination. In the 
absence of direct neuropathological examination the Boston Criteria, based on age, 
clinical and radiological criteria are commonly used for research. They were 
validated more than a decade ago and showed high specificity, but moderate 
sensitivity [48].  In a Dutch study the sensitivity of the Boston Criteria improved with 
the use of T2* weighted  MRI  and inclusion of  microbleeds  [49]. Since then 
susceptibility weighted imaging (SWI) MRI has gained importance in the detection of 
microbleeds [50].  
1.6.4 Leukoaraiosis 
Leukoaraiosis (LA) is a common finding in CT and MRI of stroke patients. It is the 
radiological appearance of tissue changes in the white matter of the brain. It is a 
feature of cerebral small vessel pathologies including hypertensive arteriopathy, 
amyloid angiopathy and CADASIL. Pathogenesis of LA is probably multifactorial. A 
proportion  of LA is caused by small infarcts in the periventricular white matter in 
patients with small vessel disease [51]. The severity of LA on CT or MRI is usually 
graded with a visual rating scale [52, 53].   
LA has been shown to be associated with an increased risk of total stroke (ischemic 
stroke or ICH). Recently it was shown in the Framingham Heart Study  that severe 
LA at baseline more than doubled the odds of future stroke and all cause mortality, 
and quadrupled the odds of dementia [54] . Stroke subtypes however were not 
assessed. No studies have assessed the association between LA and the risk of ICH in 
an unselected population. However a decade ago LA was shown to be a dose 
dependent risk factor for OAT-ICH in patients who receive OAT after an ischemic 
stroke. The association was seen for both lobar and deep cerebral OAT-ICH  [55].  
LA has also been shown to be an independent risk factor for ICH after thrombolytic 
treatment for acute ischemic stroke [56] 
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1.6.5 Oral anticoagulant treatment 
Oral anticoagulant treatment (OAT) increases the risk for ICH. The rate is 7-10 fold 
that of the non treated population [57].  In the United States a fourfold increase in the 
rate of OAT related ICH (OAT-ICH) was shown between 1988 and 1999 and linked 
to the increasing use of warfarin in atrial fibrillation in the elderly [58].  Most cases 
of OAT-ICH occur with  an International  Normalized  Ratio (INR)  within the 
therapeutic range, but  it has been shown that  increasing intensity of anticoagulation 
is associated with increased  risk of getting an OAT-ICH  and increased mortality in 
those who suffer it  [57, 59]. 
It has been suggested that OAT merely unmasks hemorrhages that otherwise would 
have remained asymptomatic; that risk factors for OAT-ICH are the same as for ICH 
in persons without OAT and that the risk of getting an OAT-ICH is the risk of ICH in 
a person without OAT multiplied with a factor which represents the intensity of  
anticoagulation [57, 60].  
Hence the risk of both lobar and deep cerebral ICH increases with OAT. This might 
explain that the relative distribution of ICH locations is not different between patients 
with and without OAT [57, 59, 61].   
European data on occurrence of OAT-ICH are scarce regarding both the incidence 
and the relative proportion of OAT-ICH in total ICH.  In a review from 2006 an 
annual incidence of 2-9 per 100.000 per year was estimated [57].  This was based on 
a proportion of 12% OAT-ICH in Southern Sweden in 1996 and available incidence 
data for total ICH [57, 61].  
Prior to the present study no Norwegian data on occurrence and outcome of OAT-
ICH existed  
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1.6.6 Race 
Racial variations have been shown with increased rates of ICH in Hispanic, Asian 
and African-American populations [42, 62-64]. Racial differences are most 
prominent for deep cerebral hemorrhages and in young and middle aged [64, 65]. 
Two studies from the United States have shown an age dependent race difference 
with a 5-6 fold increased rate  in African-Americans at age 45 compared to whites, 
but no increased rates in the highest age groups  [63, 66] .  
1.6.7 Genetic factors 
Apolipoprotein E4 and E2 are associated with lobar ICH. Recently it has been shown 
that Apolipoprotein E4 may also be associated with deep cerebral ICH [67]. Having a 
first degree relative who has had an ICH is an independent risk factor for both lobar 
and non lobar ICH [68]. 
1.6.8 Lifestyle 
In a recent large case control study performed in 22 countries 3000 stroke patients of 
whom 663 (22%)  had ICH were compared with 3000 stroke free controls matched 
for age and sex.  Hypertension, smoking, waist-to-hip ratio, diet and alcohol intake 
were significant risk factors for ICH.  Regular physical activity was associated with a 
reduced risk of stroke which was significant for all stroke and ischemic stroke. For 
ICH alone the association was not statistically significant, but the direction was the 
same [69].  
1.6.9 Low cholesterol and statin therapy 
A finding in several studies that is poorly understood is that higher total cholesterol 
and lower HDL cholesterol have been associated with reduced risk of ICH [69, 70]. 
In one study which included ICH location this association was found for non lobar 
ICH, but not for lobar ICH [71].  
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There has been concern that the use of statins may increase the risk for ICH. A post 
hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels 
(SPARCL) showed an increased risk of ICH in patients randomized to 80 mg 
atorvastatin compared to controls [72]. A pooled analysis of four randomized studies 
including 8832 patients showed a significant  1.7 (1.19-2.50) fold increased risk of 
ICH in patients on statin therapy compared to controls [73]. However a more recent 
and larger meta-analysis of 31 randomized studies including 91 588 patients on statin 
therapy and 91 215 controls showed no increased risk of ICH in patients on statins. 
Statin therapy was associated with a significant reduction in total stroke and all cause 
mortality [74].   
1.7 Outcome after Intracerebral Hemorrhage 
1.7.1 Short term mortality 
The 30-day mortality in ICH is high, between 40 and 50% in most studies [75]. In a 
recent review of population based studies the median 30-day mortality was 40.4% 
(range 13.1-61.0%) and the median 1-year mortality was 54.7% (range 46.0-63.6%) 
[9]. Short term mortality is higher than in ischemic stroke in a time dependent 
manner. In a study from Denmark there was an initial 4-fold excess mortality risk in 
ICH compared to ischemic stroke. After 1 week it was 2.5-fold. After 3 weeks it was 
1.5-fold. After 3 months there was no difference in mortality [76]. 
Factors consistently found to be associated with 30-day mortality include age, GCS 
score, ICH volume, ICH location, presence of intraventricular hemorrhage and OAT 
[11, 19, 61, 77-81]. The single most important prognostic factor for 30-day mortality 
is the initial ICH volume. [81]. The association between 30-day mortality and ICH 
volume also relates to ICH location. If lobar and deep cerebral  hemorrhages are 
equally sized,  the lobar are more often survived [81].  
Numerous prognostic tools have been created based on the most consistently found 
prognostic factors [82]. 
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1.7.2 Long term mortality 
The median 1-year mortality was 54.7% (range 46.0-63.6%) in review of population 
based studies [9]. For longer term mortality rates, data are fewer.  Mortality was 49% 
at 3 years in a study from Sweden [19] and  75% at 5 years in a study from Finland 
[83].   
Factors found to be associated with long term mortality include age, male sex, 
diabetes mellitus, anticoagulation, heart disease, ICH location and volume [19, 78, 
83, 84].  
Of the studies providing these data only one, performed in Finland more than 20 
years ago, specifically assessed mortality in those who had survived the first month 
[83]. Prior to the present study, data on factors associated specifically with long term 
mortality after the early phase were therefore very limited.  
Mortality – association with Leukoaraiosis 
There is increasing evidence of an association between severe LA and outcome in 
ischemic stroke [51, 85, 86].  For intracerebral hemorrhage we have found only two 
studies reporting an association between LA and outcome, both from South Korea. A 
single center study showed an increased 90 day poor outcome (dependency or death, 
mortality not specified) and a nationwide multicenter study of 1321 patients showed 
that LA was associated with increased early and long term mortality. Both studies had 
a low mean age of 60 years [87, 88].   
Prior to the present study no European studies and no studies based on unselected 
patients regarding age and severity have included LA in prediction of mortality in 
ICH. 
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Mortality – need for new data 
Based on the points made above there was a need for more data on LA as an 
independent prognostic factor for short and long term mortality. There was also a 
need for more data on long term mortality assessed specifically in those who survive 
the early phase. 
1.7.3 Functional dependency 
Overall there are very limited data on functional outcome in ICH, particularly long 
term data. In a recent review the authors concluded that more data on functional 
outcome after ICH are needed [9].  The scarcity of data can be illustrated by a 
frequently quoted estimate that only 20% will be functionally independent at six 
months. This is for instance quoted in the American guidelines for management of 
ICH [5]. It is based on the Oxfordshire Stroke Study. It is nearly thirty years old and 
the number of cases was low.  In total 66 patients with verified or probable ICH were 
included, 35 were imaging confirmed, 22 with autopsy and 9 non-confirmed. At 6 
months 14 patients (21%) were functionally independent [89]. In another publication 
from the same cohort patients alive after 1 year (n=25) were followed up at their 
places of residence by study nurses. After 1 year 17 of 25 survivors (68%) were 
functionally independent [90].  This latter report is of particular interest for the 
current study since, to the best of our knowledge; it is the only prior study that has 
used a direct in person follow up of long term survivors of ICH. The survivors 
included both verified and probable cases of ICH. The overall imaging rate in the 
study was 80%, but in the highest age group stroke of “unknown type” was most 
common. 
The largest study that we have found, and the largest cited in a recent review [9],  that 
reported  long term functional outcome was performed in Finland twenty years ago 
[91]. It was based on 158 consecutive unselected patients with ICH. Functional status 
was assessed by use of a telephone interview of patients or care givers.  After a 
median follow up of 2.7 years there were 55 survivors of whom 28 (51%) were 
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independent in activities of daily living. Age >70 years was the only identified factor 
independently associated with a poor functional outcome [91].   
In a study from Estonia 14 of 26 (54%) one-year survivors of ICH were functionally 
independent [92].  A questionnaire sent by mail was used to score the BI from which 
independence defined as mRS<3 was derived.  
1.7.4 Cognitive impairment 
Very few data on cognitive impairment in survivors of ICH exist; a paradox 
considering that ICH is a common and serious disease of the brain.  
In a study in the United States restricted to lobar ICH severe white matter changes 
were independently associated with cognitive impairment that existed prior to the 
ICH, but not with development of incident cognitive impairment during follow up 
(mean 32 months). The authors suggested an underlying vasculopathy, possibly CAA 
causing cognitive impairment. Pre-ICH cognitive impairment was assessed with a 
questionnaire after the ICH and incident cognitive impairment was assessed by 
telephone interview [93]. 
In a recent study from France, 48 of totally 80 survivors of ICH underwent 
assessment for cognitive impairment with a neuropsychological examination. 
Cognitive impairment was found in 77%. The 48 who were examined were younger, 
had less disability and more rarely lived in nursing homes than the survivors who 
were not examined and were therefore a selection. No analysis of prognostic factors 
for cognitive impairment was reported. 
Overall data on cognitive impairment based on survivors with the full range of 
clinical severity and data based on a face to face follow up are very scarce. To the 
best of our knowledge no prior data exist on associations between cognitive 
impairment and ICH location.  
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1.7.5 Recurrent ICH 
In a systematic review of 10 studies the overall rate of recurrent ICH was 2.3% per 
patient-year. It was higher after lobar than deep cerebral index ICH (4.4% versus 
2.1% per patient year, p 0.002) [94].   In a study from the United States the results 
were similar with an overall recurrence rate of 2.4 % per year and an  increased the 
risk with lobar location with an OR of 3.8 [95].   
Overall the rate of recurrent ICH is similar across studies, but findings are conflicting 
regarding an increased risk associated with lobar index ICH.  In Izumo City, Japan, 
the annual recurrence risk was also 2.3%. Lobar location was not associated with 
increased risk [96]. It has been speculated that this could express an epidemiological 
difference between an Asian and a Caucasian population [75]. However there are also 
studies from Sweden [19] and Finland [97] in which there was no higher risk of 
recurrent ICH after lobar compared to deep cerebral index ICH.   
In an MRI based follow up study of survivors of lobar index ICH an increasing 
number of macro and micro hemorrhages on the baseline gradient echo MRI was 
associated with an increased risk of recurrent ICH [98]. 
1.7.6 Late seizures 
Early seizures after an ICH have been reported in 4-16%, with varying definitions of 
early from 7 to 30 days  [99-102], and are associated with lobar ICH location [100].  
Data on late seizures, occurring after the acute phase of an ICH, however are fewer. 
In a multicenter study of 2021 stroke patients 7 of 265 patients with ICH (2.6%) 
developed late seizures defined as after 2 weeks. Mean follow up time was 9 months 
[102].  
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1.8 Acute treatment  
General stroke treatment and monitoring 
Both European and American guidelines recommend that patients with acute ICH 
should be monitored and treated in specialized units [1, 4, 103].  
In a controlled trial in Norway, patients with ICH were allocated to either a general 
medical ward (n=65) or a stroke unit (n=56). The study showed a significant 
reduction in 1-year mortality in the stroke unit group driven by a difference in the 
first 30 days [104] .   
In the United States the mortality has been shown to be lower in patients treated in 
intensive-care neurology units compared with general intensive care units  (ICU) 
[105] and associated with the frequency of use of do-not-resuscitate orders [106]. 
Admissions for ICH to urban teaching hospitals increased from 30% to 49% over a 
decade from 1990-1991 to 2000-2001.  Mortality decreased substantially in urban 
teaching hospitals, but not urban non-teaching hospitals and rural hospitals [107].  In 
a recent review the authors suggest that these studies provide indirect evidence that 
aggressive medical management and specialist care can improve the overall outcome 
in patients with ICH and that the changing trends in admissions might be beneficial 
[65].  Recently 26 quality indicators for the systematic evaluation of ICH patient care 
were proposed. Validation and further refinement of the indicators are planned [108]. 
Acute blood pressure lowering 
The results from Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage 
Trial (INTERACT) 2 were released at the European Stroke Conference on May 29th 
2013 and published simultaneously online in the New England Journal of Medicine 
[109]. In this large phase 3 trial 2839 patients with ICH within the last six hours were 
randomized to either intensive blood pressure treatment (target systolic level of <140 
mm HG within 1 hour) or guideline-recommended treatment (target systolic level of 
<180 mm HG). The choice of agent was left to the treating physician. The primary 
endpoint of death or major disability (mRS 3-6) after 90 days showed a trend towards 
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significance (p=0.06) with this endpoint being reached in 52.0% in the intensive 
group and 55.6% in the guidelines group, OR 0.87 (0.75-1.01). As discussed in the 
paper and the accompanying editorial [110] there was a significant treatment benefit 
when using an ordinal analysis of the mRS or (p=0.04)  or the common dichotomy of  
mRS 2-6 (p=0.03).  Health related quality of life after 90 days was significantly better 
in the intensive treatment group. There was no increase in adverse effects by 
intensive treatment. The editorial concludes that “given the trend toward significance 
for the primary endpoint, the significant improvement in secondary endpoints and the 
reassuring safety, acute blood pressure lowering to a target systolic blood pressure of 
140 mm Hg appears to be a “reasonable option”. “Reasonable” is a preferred wording 
in recommendations based on level B evidence in American guidelines. The 
thresholds for blood pressure lowering in the current guidelines are based on expert 
opinions (level C) [1]. The new INTERACT 2 data are now the best data available 
and it is likely that guidelines will be changed although probably still not with the 
highest level of evidence.  
INTERACT 2 can be the start of a breakthrough in ICH management. We may see a 
new perception of ICH as a no time to lose emergency equal to ischemic stroke. 
Potentially it can influence the choice and design of environments for the hyperacute 
care of patients with ICH.  Many traditional Scandinavian model stroke units may not 
be adequately staffed and equipped for semi intensive care for patients with ICH. An 
upgrading of stroke units or a shift towards initial allocation of patients with ICH to 
an ICU are possible consequences. 
Hemostatic therapy 
The effect of recombinant factor VIIa (rFVIIa) given within four hours after symptom 
onset in ICH has been studied in two large randomized, blinded, placebo-controlled 
trials. The first study showed a marked reduction in haematoma growth, and 
improved clinical outcome [111]. The second study reproduced the finding of 
reduced hematoma growth, but disappointingly did not show significantly improved 
clinical outcome [112]. It has been suggested that a clinical treatment effect may have 
escaped significance in the second study due to the study design. A post hoc analysis 
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showed that a subset with age ≤70 years, ICH volume <60 ml, intraventricular 
hemorrhage volume <5 ml, and time from onset-to-treatment <2.5 hours may benefit 
from treatment [113].  The currently recruiting study Spot Sign for Predicting and 
Treating ICH Growth (STOP-IT) compares rFVIIa with placebo in patients with spot 
sign positive baseline CTA and hence an increased risk of hematoma expansion and 
poor outcome [114]. 
Another attractive candidate for haemostatic therapy is tranexamic acid.  Several 
ongoing and planned studies compare tranexamic acid with placebo with [115] or 
without [116]  including the spot sign in the selection of patients.  
Early surgery  
Early surgery for acute ICH is still controversial. A Cochrane review of 10 trials with 
a total of 2059 patients showed a statistically significant benefit of surgery with 
reduced odds for death or dependency, but the authors conclude that the result is not 
very robust and that further randomized trials are indicated to identify which patients 
benefit from surgery and to evaluate less invasive methods [117]. The International 
Surgical Trial in Intracerebral Haemorrhage (STICH) trial (n=1033) published in 
2005 showed no benefit from early surgery (at a median time of 30 hours from 
symptom onset) compared to conservative treatment [118]. The results from STICH 2 
were released at the European Stroke Conference on May 29th 2013 and published 
simultaneously online in the Lancet [119]. This trial tested if a subgroup of conscious 
patients with superficial lobar hemorrhages (<1cm from the brain surface) and no 
intraventricular hemorrhage would benefit from early surgery (<12 hours) compared 
to initial conservative treatment. The primary endpoint was a prognosis based 
dichotomized favorable or unfavorable outcome that adjusted for age GCS and ICH 
volume. An unfavorable outcome was seen in 59% in the early surgery group and 
62% in the initial conservative group. This was not statistically significant (p=0.367). 
There was a significant benefit of early surgery in a subset with poor prognosis. 
However the authors underline that this was not a prespecified endpoint and therefore 
needs cautious interpretation. There was a large crossover with 21% in the 
conservative group having delayed surgery. The authors conclude that early surgery 
 28 
does not increase the rate of death or disability and that there might be a small but 
clinically important benefit of early surgery [119]. Both the original paper and the 
accompanying comment [120] emphasize the persisting uncertainty as to which 
patients might benefit from early surgery and call for more data, in particular within 
the field of minimally invasive surgery.  
Minimally invasive surgery combined with catheter delivered tissue plasminogen 
activator (rtPA) has shown promise. The Minimally Invasive Surgery plus rtPA for 
supratentorial ICH with volume >20 ml were randomized to either a control group 
(n=39) or to active treatment (n=54) with a CT guided minimally invasive surgery 
(MIS) procedure with application of a catheter into the clot and a three times daily 
injection of 1 mg rtPA for 1-3 days and drainage of superfluous liquid through the 
catheter. One year follow up results were presented at the International Stroke 
Conference in February 2013. The active treatment group had better outcomes than 
the control group on several measures including mRS, length of hospital stay, need of 
nursing home and costs [121]. A larger phase 3 trial is planned aiming to confirm 
these encouraging findings. 
In patients with intraventricular hemorrhage (IVH) a common complication is 
obstructive hydrocephalus. Recent studies have shown that application of rtPA 
through a catheter directly into the intraventricular blood clot safely enhances clot 
resolution [122, 123].  A larger phase 3 study  is currently recruiting [124].  
For cerebellar hemorrhages there are no randomized data to guide treatment 
decisions. However the ASA guidelines (2010) state that the differences in outcome 
in the earlier non randomized studies are such that clinical equipoise does not exist 
for a trial. Therefore it is recommended that ”patients with cerebellar hemorrhage 
who are deteriorating neurologically or who have brainstem compression and/or 
hydrocephalus from ventricular obstruction should undergo surgical removal of the 
hemorrhage as soon as possible” [1].  
  
ICH Evacuation (MISTIE) trial was a proof of concept trial. Patients with an acute 
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Acute treatment – summary 
In summary as of July2013 it seems likely that guidelines and clinical practice will 
change as the result of INTERACT II with rapid blood pressure lowering as a 
standard treatment that is safe and probably beneficial. The answer to the question of 
which patients may benefit from early surgery is unfortunately still not clear. The 
results from the studies of minimally invasive surgery are eagerly awaited.     
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2. Aims of the thesis 
The overall aim of this project was to assess the incidence, characteristics and 
outcome of ICH in Southern Norway.  
Aims: 
1. To assess the incidence and baseline characteristics of first ever ICH in 
Southern Norway leading to hospitalization (Paper I). 
2. To assess short- and long term mortality after first ever ICH (Paper I and II). 
• Mortality rates at standardized time points; 2 days, 7 days, 30 days, 1 year, 
and two years (Paper I and II). 
• Baseline factors associated with 30-day mortality and with long term 
mortality in those who survive the first 30 days (Paper II). 
3. To assess the rate of recurrence after first ever ICH (Paper II). 
4. To assess the clinical functioning in long term survivors (Paper III). 
a. Functional dependency – rate and association with baseline factors  
b. Cognitive impairment – rate and association with baseline factors 
5. To assess the rate of late seizures occurring after the index hospital stay (not 
published). 
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3. Materials and methods 
3.1 Study population and area 
Sørlandet Hospital Kristiansand in Vest-Agder County in Southern Norway serves a 
well-defined core catchment area from which all patients with acute stroke are 
admitted to the department of neurology 24/7/365. The population on January 1st of 
the midyear 2007 was 152276.Approximately 80.000 live in the city of Kristiansand, 
and the rest in smaller towns and rural areas.   
Cases were found by computer search in the hospital register for all in- and 
outpatients with International Classification of Disease 10 (ICD 10) codes I61, I62 
and I64.   
For Paper I and II all consecutive patients hospitalized with a first ever ICH in the 
five year period 2005-2009 were included. Cases with traumatic ICH, ICH related to 
intracranial malignant tumor, ruptured aneurysm, or thrombolytic treatment and cases 
with isolated intraventricular hemorrhage without visible affection of cerebral 
parenchyma were excluded. Patients from the study area who were hospitalized 
elsewhere with ICH and subsequently transferred to SSK were included. 
For the long term follow up study (Paper III) all patients in the initial cohort who 
were not registered as dead were contacted and invited to participate. Patients or care 
givers were first contacted by telephone. The reasons for this approach were two fold. 
Firstly, since we did not know the functional status of each individual or the ability to 
comprehend written information about the research project, we expected a direct 
contact by telephone to carry a lower risk of causing insecurity and anxiety than a 
letter. Secondly we assumed that the response rate would be higher with the use of 
telephone.  If no contact was obtained by telephone a written invitation was sent. The 
means of obtaining contact were approved by the regional committee of medical 
research ethics.  
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3.2 Baseline assessment 
Risk factors 
Risk factors were recorded in a stroke registry from September 2007 and retrieved 
from patient files in cases prior to that. Hypertension and diabetes mellitus (diabetes 
mellitus, insulin-dependent or -independent) were defined as present if a history was 
known. Atrial fibrillation was defined as present if documented prior to or during 
hospital stay. Coronary heart disease (CHD) was defined as having had an acute 
myocardial infarct, coronary bypass surgery or percutaneous coronary intervention.  
Clinical severity 
Glasgow Coma Scale score (GCS) score was categorized into three groups 3-4, 5-12 
and 14-15. These are the cut offs used in the ICH score published by Hemphill et al 
[77]. 
Imaging 
All patients had a non contrast CT scan at baseline. One of the authors (AT) assessed 
all CT images. Hematoma location was classified as lobar (predominantly cortical or 
subcortical white matter), deep cerebral, brainstem or cerebellum. Thalamic 
hemorrhages were allocated to the category deep cerebral. The category brain stem 
included pontine and mesencephalic hemorrhages. Hematoma volume was calculated 
with the A x B x C /2 formula. The CT slice with the largest area of hemorrhage is 
identified. A is the greatest diameter of the hemorrhage,  B is the diameter 90° to A, 
and C is the approximate number of CT slices with hemorrhage multiplied by the 
slice thickness [125]. The presence of intraventricular blood was registered. The 
severity of LA was graded as described by Van Swieten. The anterior and posterior 
regions were examined separately. LA was distinguished from infarction by its ill-
defined borders. The severity of hypodensity, if present, was expressed in one of two 
degrees for each of the two regions. In grade 1 the abnormality was restricted to the 
region adjoining the ventricles. In grade 2 the increased hypodensity involved the 
 33 
entire region from lateral ventricle to the cortex. The scores of the two regions were 
added giving an overall score from 0 to4 [126].  
 
3.3 Outcomes assessment 
Mortality 
Death was automatically updated monthly through a linkage to the National 
Population Register [127]. The follow up was closed on 31.12.11. Patients not 
registered as dead by this date were considered alive. Causes of death, updated to 
31.12.11, were obtained from the cause of death registry/Statistics Norway [128]. In 
addition, patient files were reviewed for clinical and radiological information on 
cause of death.  
Recurrent ICH 
In all patients who were discharged alive we checked for recurrence of ICH by 
combining information from the cause of death registry and from review of patient 
files and interview with the patients and care givers at follow up for information on 
readmission, neuroimaging or outpatient contact. 
Functional dependency 
The Barthel Index (BI) measures dependency in activities of daily living (ADL), by 
scoring  three degrees of dependency for ten common ADL activities  giving a total 
score from 0 (complete dependency) to 100 (complete independency). Eight of the 
ten items represent activities related to personal care; the remaining 2 are related to 
mobility. It is one of the most used measures of functional disability  [129]. The scale 
was introduced in 1965 [130]. It has later been refined [131, 132]. 
The modified Rankin Scale (mRS), shown in Table 1, is a widely used global 
outcomes rating scale for stroke patients. It measures the ability to perform activities 
 34 
the patient carried out previously.  It was first developed in 1957 and was modified to 
its current form in 1988 [133, 134]. It ranges from 0 (no symptoms at all) to 6 (dead) 
[129]. In the present study mRS 3-5 was defined as dependency.  
 
Table 1 Modified Rankin Scale (mRS) 
Grade Description 
  
0 No symptoms at all 
1 No significant disability, despite symptoms; able to carry out all usual 
duties and activities 
2 Slight disability; unable to carry out all previous activities, but able to 
look after own affairs without assistance 
3 Moderate disability; requiring some help, but able to walk without 
assistance 
4 Moderate severe disability; unable to walk without assistance and 
unable to attend to own bodily needs without assistance 
5 Severe disability; bedridden, incontinent and requiring constant 
nursing care and attention 
6 Dead 
 
 
Cognitive impairment 
The Montreal Cognitive Assessment (MoCA) is a brief screening tool designed to 
detect mild forms of cognitive impairment not captured by other cognitive screening 
instruments. It contains the following six domains: memory, visuospatial ability, 
executive functioning, attention and concentration, language, and orientation The 
maximum total score is 30 [129]. In the original publication a cut off at 26 points was 
recommended with scores ≤ 25 indicating the presence of cognitive impairment 
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[135]. More recent studies however have found improved balance between sensitivity 
and specificity with a lower cut-off [136, 137]. In the current study we used the cut 
off ≤ 23 recommended as the optimal by Luis et al., providing both excellent 
sensitivity and specificity for detecting mild cognitive impairment [136]. We used the 
approved Norwegian version of the MoCA [138]. 
Late seizures 
Patient files of the long term survivors were reviewed for clinical and radiological 
information on readmission, neuroimaging or outpatient contact between the Index 
ICH and the follow up. At the long term follow up we asked the patient and 
accompanying relatives, friends or care givers about seizures occurring after 
discharge for the index ICH. 
3.4 Statistics 
For the calculation of incidence (Paper I) we used the population on January 1st of the 
midyear 2007. Pearson’s Chi Square, Fisher’s exact test, a t test, one-way ANOVA, 
Mann-Whitney, Pearson Correlation, the Spearman Rank Order Correlation, the 
Mantel-Haenszel test, logistic regression and Cox proportional hazard regression 
were used as appropriate. Statistical analysis was performed with SPSS version 18. 
3.5  Ethics approval 
The study was approved by the regional committee of medical research ethics (S-
07227a). 
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4. Summary of results 
In total 134 patients were hospitalized with first ever ICH in the period 2005-2009. 
Ethnicity was Caucasian in 97.8%. Age ranged from 33 to 100 years. Fifty five 
percent were men and 45% were women. Men were significantly younger than 
women (72.9 versus 78.2 years, p=0.010).  
4.1 Incidence (Paper I) 
The crude annual incidence rate per 100.000 was 19.6 for men, 15.7 for women and 
17.6 for both sexes.  Adjusted to the standard European population it was 16.9 for 
men, 8.8 for women (p<0.001) and 12.5 for both sexes. The incidence rates rose 
continuously with increasing age through all age groups in both sexes. The overall 
age adjusted rate ratio men/women analyzed with the Mantel-Haenzel test was 1.78 
(p=0.001) 
4.2 Hematoma location (Paper I) 
The hematoma location was lobar in 36.6%, deep cerebral in 45.5%, cerebellar in 
9.7%, and brain stem in 8.2%.  Intraventricular hemorrhage occurred in 37% and was 
more frequent in patients with deep cerebral than lobar hematomas (50.8% versus. 
24.5%, p=0.005).  
4.3 Oral anticoagulant treatment associated ICH (Paper I) 
The proportion with OAT-ICH was 26.9%. The annual incidence of OAT-ICH was 
4.7 (95% CI 3.4-6.5) per 100.000.  The median international ratio (INR) was 2.6 
(interquartile range 2.2-2.9). Only 2 patients (5.6%) had an INR of more than 4. The 
cause for taking warfarin was atrial fibrillation in 30 of 36 patients (83.3%). Warfarin 
users were older than non users (78.6 versus 74.0 years, p=0.054) and more often had 
hypertension (70.6% versus 49.0%, p=0.029), atrial fibrillation (83.3% versus 5.1%, 
p<0.001) and a previous TIA or ischemic stroke (33.3% versus 16.3%, p=0.032). The 
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median ICH volume was non-significantly greater in warfarin users versus non users 
(25 ml (IQR 13-68) versus 17 ml (IQR 5-39), p=0.065). 
4.4 Early hospital admission (Paper I) 
The proportion of patients admitted within 3 hours of symptom duration was 49% for 
men, 32% for women (p=0.047) and 41% for both sexes.  
4.5 Mortality (Paper I and II) 
4.5.1 Mortality rates (Paper I and II) 
Overall mortality at 2 days was 23.1%, at 7 days 29.9%, at 30 days 36.6%, at 1 year 
46.3%, and at 2 years 53.0%. 
After a median of 4.7 years (inter quartile range 2.5-6.6) follow up 84/134 patients 
(63%) were dead. There were 85 30-day survivors of whom 35 died.  
4.5.2 Factors associated with 30-day mortality (Paper I and II)  
In multivariate analysis the significant factors independently associated with 30-day 
mortality were warfarin (OR 4.4, p=0.022); GCS score 5-12 (OR 9.6, p<001); GCS 
score 3-4 (OR 102.6, p<001); intraventricular hemorrhage (OR 5.7, p=0.008) and LA 
(OR 1.6, p=0.026).  
The two independent variables that showed the highest correlation were ICH volume 
and GCS score (Pearson Correlation 0.569, p<0.001). When both were included in 
the multivariate regression model GCS was a significant factor for 30-day mortality 
whereas ICH volume was not. As discussed in paper II we view ICH volume as the 
more causative of the two. When GCS score was removed from the model ICH 
volume and brain stem location were significant factors in addition to the otherwise 
unaltered warfarin, intraventricular hemorrhage, and LA score. 
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30-day mortality was 61.1% in the 36 patients on warfarin therapy versus 27.6% in 
the 99 not using warfarin (p< 0.001).  
4.5.3 Factors associated with long term mortality (Paper II)  
In multivariate analysis the significant factors independently associated with long 
term mortality in 30-day survivors were CHD (HR 2.7, p<0.001); GCS score 3-12 
(HR 3.5, p=0.008), and LA score (HR 1.6, p=0.001).  
4.6 Recurrent ICH (Paper II) 
Four of the 88 patients (4.5%) who were discharged alive after the index ICH had an 
imaging confirmed recurrent ICH during follow up. One was fatal. Recurrent ICH 
was more frequent after lobar index ICH (4/36 (11.1%)) than after index ICH in other 
locations (0/52 (0%)), (p=0.025). Median time to recurrent ICH was 42 months. 
4.7 Functional dependency (Paper III) 
Of the 51 patients alive 50 (24 men (48%) and 26 (52%) women) agreed to 
participate in the follow up study. The median time from the ICH to the final follow 
up was 3.8 years (IQR 2.7-5.6). Amongst the 50 long term survivors 34 (68%) were 
independent (mRS 0-2). Sixteen (32%) were dependent (mRS 3-5).  
There were some sex differences amongst the long term survivors. Men were younger 
than women both at baseline (66.4 versus 74.9 years, p=0.019) and at follow up (70.4 
versus 78.7 years, p=0.019). Men had more education, were more often smokers, and 
had larger hematomas at baseline than women (14 ml (IQR 5.3-23.5) versus 4.5 ml 
(IQR2.0-15.5), p=0.027).  
Forty one patients (82%) lived in their private homes and 9 patients (18%) lived in 
nursing homes.  
 39 
In multivariate analysis the significant factors independently associated with mRS 3-5 
were female sex (OR 5.1 (1.1-23.6), p=0.038) and LA score (OR 2.3 (1.3-4.0), 
p=0.003).   
4.8 Cognitive impairment (Paper III) 
The MoCA could be assessed in 44 patients (88%).  The proportion with MoCA≤23 
was 27 of 44 patients (61.4%).  
In multivariate analysis the significant factors independently associated with 
MoCA≤23 were age (OR 1.1 per year/2.4 per 10 years p=0.010) and lobar ICH 
location (OR 14.1, p=0.016).  
4.9 Late seizures (not published) 
Five long term survivors (10%) had documented late seizures after discharge from the 
index hospital stay. All were generalized tonic clonic. The mean time from ICH to 
first seizure was 2.4 (SD 2.2) years, with the first occurring after 1.1 years. None of 
these patients had known epilepsy prior to the ICH, and none had early seizures 
during the index hospital stay.  
Seizures occurred in 5 of 19 patients (26%) with lobar ICH versus 0 of 31 patients 
(0%) with ICH in other locations (p=0.005). Patients with seizures had larger median 
ICH volumes than patients without seizures, 39 ml (IQR 23.5- 58.5) versus 7 ml (7 
ml (IQR 2.5-16.5), p=0.004.  Seizures were not related to age or sex.  
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5. Discussion 
5.1 Methodological considerations 
Case finding 
Case finding was done retrospectively. This may potentially have led to the loss of 
cases. The magnitude of this risk depends on the quality of the ICD 10 coding entered 
into the hospital database. The daily clinical activity in the stroke unit of the 
Department of Neurology, Sørlandet Hospital Kristiansand was lead by the same 
senior neurologist (AT) throughout the whole study period. From 2006-2009 one 
single senior neurologist reviewed all patient files before final ICD 10 coding in the 
hospital database.  
Case finding was hospital based. As discussed in Paper I this gave a community 
based assessment of cases that lead to hospitalization. An important question is to 
which extent the number of cases with verified ICH identified by this approach 
differs from a population based stroke incidence study. Since the ICH diagnosis 
requires either brain imaging or autopsy, ICH is basically a hospital diagnosis. The 
Malmgren criteria for the “ideal stroke incidence study” were published twenty five 
years ago and have been updated later [139-143]. These include multiple overlapping 
sources of case finding. In the updated list these are in addition to hospitals: 
outpatient clinics including regular checking of general practitioners` databases and 
death certificates [143].  However none of these publications have reported data on 
which proportion of patients with verified ICH could be identified amongst out-of-
hospital cases. The only Norwegian stroke incidence study (Innherred) prior to the 
present study did not report cases of verified ICH that were identified amongst out-
of-hospital cases [13, 61]. Overall such data are extremely scarce. An autopsy based 
estimate of 5% of ICH cases being fatal out-of-hospital cases appears in a report from 
Finland twenty five  years ago [91].  
The estimated hospitalization rate was 95% of all strokes in a population based study 
from Sweden including ages 50-79 years in the period 1993-1998 [144]. This is 
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identical to the findings in the multipopulation EROS study (94.6%) in which all ages 
were included [10]. Sørlandet Hospital Kristiansand has a long history of encouraging 
rapid hospitalization of all cases of suspected stroke regardless of age sand stroke 
severity. As discussed in Paper I the finding that the incidence increased with age 
including the highest age group indicates that few cases were lost. We did perform a 
search in the hospital autopsy register for the study period. No additional cases were 
found. This information was not included in Paper I since the chosen design was 
limited to cases leading to hospitalization. It is unlikely that many fatal out-of 
hospital cases would have been verified as ICH by additional case finding methods 
such as a weekly query to general practitioners. As discussed in Paper II the quality of 
data in the cause of death registry is poor [145, 146]. Adding this source to the 
methods could have identified some cases with possible or probable strokes, but these 
would have been of undetermined subtype and it is very unlikely that additional cases 
with verified ICH would have been identified. An additional point is that the CT and 
MRI facilities lie in immediate proximity of the neurological department and any 
outpatient case revealing an unexpected ICH will trigger immediate alert of the 
neurology staff. No such cases occurred. 
The difference between a hospital based and multiple overlapping source based 
catchment approach is therefore probably not large when it comes to the specific 
subset of verified ICH. 
Incidence 
In the estimation of incidence attention must be given to both the numerator and the 
denominator. An issue rarely discussed is that in studies that include both ischemic 
and hemorrhagic strokes and at the same time include only first ever strokes, all 
patients with a first ever ICH and a known history of a previous ischemic stroke will 
be excluded. This will reduce the calculated incidence and influence the composition 
of risk factors. If the aim is to assess the incidence of first ever ICH it seems illogical 
to exclude patients because of a prior history of another disease. The current study 
and the Southern Sweden study both included patients with a prior ischemic cerebral 
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event and the proportions with prior ischemic events were very similar, 21%  and 
19% respectively [61]. 
Concerning the denominator, the population used to calculate the incidence will 
influence the crude incidence. For instance the population < 15 years is a 
considerable proportion of the total population, but have an extremely low incidence 
rate of ICH and therefore the exclusion of the population < 15 (or any other low age 
limit) will give a higher total crude incidence. The  Innherred study included ages > 
15 years [13]. In the current study the total population was used and pediatric strokes 
sought. No pediatric strokes occurred. The Southern Sweden study also reported 
inclusion of all ages and the search for  pediatric strokes [61].  
Number of cases and events 
Overall the numbers in the present study are relatively small, especially in some subgroups. 
The results must therefore be interpreted with caution. In particular the findings on 
recurrent ICH and late seizures are based on very low numbers of events. Both were 
associated with lobar ICH. This is discussed in more detail below. However the low 
numbers and the possibility that findings may be caused by the play of chance must 
be kept in mind.   
Leukoaraiosis assessment 
LA was assessed on the baseline CT. It has been shown that MRI is superior to CT in 
the detection of smaller white matter changes, but that the two modalities are equal in 
the detection of larger changes [85]. In the present study priority was given to 
completeness in scoring and therefore the baseline CT was chosen. Since MRI was 
not performed in all patients and probably in a selection of the less severely injured, 
we decided when designing the study not to include MRI in the assessment to avoid 
selection bias.   
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Long term follow up 
A major strength in this study is that in contrast to most studies all survivors had a 
direct in person follow up with a thorough examination and a comprehensive 
questionnaire. It is also a strength that none were lost to follow up and all but one of 
the survivors agreed to participate. 
The mRS at follow up was scored based on changes in abilities compared to the 
situation prior to the ICH. The patients, accompanying person, and care givers were 
asked whether each limitation in abilities that was identified was present prior to the 
ICH. However some blurring of the borders between preexisting and acquired 
limitations due to recall bias cannot be ruled out. 
Data on pre-ICH cognition were not available. A firm knowledge of pre-ICH 
cognition would be desirable, but from a practical standpoint a direct compare of an 
in person examination like the MoCA before and after the ICH is probably 
unachievable. Therefore importantly the present study assessed the rate of cognitive 
impartment irrespective of which proportion was caused by the ICH.
 
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5.2 Discussion of results 
5.2.1 Incidence (Paper I) 
An overall interpretation is that the current age-adjusted  incidence of first ever ICH 
of 12.5 per 100000 per year  in Southern Norway is in the mid range of recent 
population based findings in Europe [10]. The present study does not support that an 
incidence in the higher range in Europe as found in the only prior Norwegian study 
reflects the current situation in Southern Norway [13, 61].  Additional support for this 
interpretation is provided by a population based study from Iceland, published online 
in may 2013, reporting a crude annual incidence of 13 per 100.000 in 2007/2008  
[147]. The incidence in the present study is probably representative and unlikely to be 
substantially underestimated. 
A possible contributor to a lower incidence than seen in prior Scandinavian studies is 
improved blood pressure control. In several countries including Sweden, Denmark 
and Finland a decreasing prevalence of hypertension has been found and blood 
pressure control has improved [148-151].  There are no Norwegian studies on trends 
in the quality of blood pressure control. However the sales statistics clearly show a 
markedly increased sale of blood pressure lowering medication over the last two 
decades (Figure 1).  
The present study contains the first Norwegian data on the sex distribution of ICH. 
The incidence was higher for men than women. Our findings thereby support that 
men are at higher risk than women for ICH in Southern Norway in line with the 
dominating finding in the EROS study where five out of six centers had a male 
predominance. Men also had increased risk in Southern Sweden in 1996 [61]. 
Summing up these elements of evidence, the present study contributes to a now solid 
indication of an increased risk in Scandinavian men versus women that is 
reproducible over time and in different regions.   
The incidence in our study increased with age through all age groups in both sexes. 
Some studies including two Scandinavian studies have shown a decreasing incidence 
in the highest age group [13, 61]. As discussed in Paper I it has been suggested that 
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incomplete case finding and stroke subtype classification can be contributing factors 
to this otherwise surprising finding [9].  The current study supports the more intuitive 
continuous association between age and risk. Our finding is supported by a recent 
report from Dijon, France. In the 24 year period from 1985 to 2008 a time trend was 
evident with an increase of the incidence (nearly doubled) in the highest age group, 
and a decrease in the lowest age group. Importantly, a lower cut off (>75 years) was 
used to define the highest age group, but the finding is still of interest. Through the 
whole time period the highest incidence was found in the highest age group. The 
authors link the increase in the incidence in the highest age group to trends in the use 
of antithrombotic treatments. The total crude incidence was stable [152].  
 
 
Figure 1  Sales of antihypertensives (C02), diuretics (C03), beta blocking agents 
(C07) calcium channel blockers (C08) and ACE inhibitors/angiotensin II antagonists 
(C09) 1990-2012 in DDD/1000 inhabitants/day 
 
Source: Sakshaug S. Drug Consumption in Norway 2008-2012 (Legemiddelforbruket 
i Norge 2008-2012), Norwegian Institute of Public Health, Oslo, legemiddelstatistikk 
2013:1. 2013. [153] 
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5.2.2 Hematoma location (Paper I) 
There were more deep cerebral than lobar hemorrhages. This is in agreement with 
several previous studies and the proportional distribution of locations is almost 
identical to findings in Jyvaskyla region, Finland and Greater Cincinnati, USA. This 
is illustrated in Table 2 (not published).  In Southern Sweden the opposite relation 
was found with more lobar than deep cerebral ICH [61].  No previous Norwegian 
data exist. The present study supports that there is a moderate predominance of deep 
cerebral ICH in Southern Norway in general agreement with studies cited in both 
American and European guidelines [4, 5].  Deep cerebral location was associated 
with hypertension and smoking. 
The proportion of patients with intraventricular hemorrhage (37%) was in agreement 
with findings by others ranging from 36% to 42% [17-19]. 
 
Table 2  Proportional distribution of ICH location in Kristiansand and other studies
(not published) 
 Total  Lobar Deep cerebral Brain stem Cerebellum 
 n % % % % 
Kristiansand, present study 134 37 46 8 10 
Greater Cincinnati, USA 1038 35 49 6 10 
Izumo City, Japan 350 15 69 9 25 
Southern Sweden 341 52 36 4 9 
Jyvaskyla region, Finland 158† 34 49 7 11 
Dijon, France 87 18 67 6 9 
Perth, Australia 60* 40 52 7 10 
*13 'massive cortical' hemorrhages included in the deep group. †9 intraventricular 
hemorrhages included in the deep group. 
Source: [16] 
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5.2.3 OAT-ICH (Paper I and II) 
The present study provides data on the burden of OAT-ICH from a setting in which 
anticoagulant therapy for atrial fibrillation in the elderly was reasonably well 
implemented and still entirely warfarin based.  It may serve as a reference for future 
studies. 
The study provides supportive evidence of a rise in the proportion of OAT-ICH 
amongst total ICH and confirms a very poor prognosis of OAT-ICH. Consistent with 
several other reports most cases occurred with therapeutic levels of the INR [58, 154, 
155]. Therefore the high proportion of OAT-ICH amongst total ICH can be viewed as 
the calculated risk of the active treatment policy. The finding is not an argument for 
withholding anticoagulant treatment in elderly patients with atrial fibrillation given 
the high level of evidence of its beneficial effect in the prevention of ischemic stroke 
[156]. However it does address the need for a careful individual approach particularly 
in the oldest patients. The burden of OAT-ICH is also highly relevant for 
current ongoing shift towards new oral anticoagulants. As of July 2013 recent changes 
in reimbursement have boosted this shift in Norway. What the burden of OAT-ICH is 
after an anticipated greater shift towards the new agents needs to be seen.  The new 
agents may carry a lower risk of OAT-ICH. A more liberal prescription policy could 
however possibly to some extent counterbalance this, a scenario hopefully avoided 
through adherence to evidence based implementation.    
5.2.4 Early hospital admission (Paper I) 
The proportion admitted within three hours of symptom duration was 41% (Paper I). 
It was higher in men than women and higher than the corresponding proportion for 
ischemic stroke (23%) in our center [157]. This proportion is rarely reported but 
highly relevant for the eligibility to acute treatments. It is also important for the 
planning of studies of acute treatments. Based on the present study the inclusion 
criteria hospital admittance < 3 hours and ICH volume < 60 ml would retain 31% of 
the patients and give approximately 5.5 eligible patients per 100.000 inhabitants per 
year. If age < 80 years is added to the criteria, the number drops to 3.5. Additional 
 48 
exclusion criteria such as warfarin use or a GCS score cut-off will further reduce the 
number. This readily illustrates the likely need for multinational studies for testing 
treatment effects on clinical endpoints if for instance a sample size of 500-1000 is 
required.  
5.2.5 Mortality rates (Paper I and II) 
The overall mortality rates of 23.1 %, 29.9 %, 36.6 %, 46.3 % and 53.0 %, at 2 days, 
7 days, 30 days 1 year and 2 years  respectively  are in general agreement with 
previous reports [10, 19, 78, 83, 84, 158, 159].  
5.2.6 Factors associated with 30-day mortality (Paper I and II) 
We identified warfarin, GCS score, intraventricular hemorrhage, and LA score as 
independent prognostic factors for 30-day mortality.  
The prognostic impact of LA is discussed separately below.  
Warfarin was as expected a significant independent prognostic factor for 30-day 
mortality as seen in several studies [58, 155, 160]. Importantly, the present study 
confirmed this in an unselected cohort with many old patients. The very high 30-day 
mortality of 61.1% in warfarin users is similar to several prior studies [161-163].  
Others have found somewhat lower rates, 52% in the united States  [59]  and 54% in 
Finland  [155]. A 30-day mortality in OAT-ICH in the higher end in the present study 
might be explained by the high age and comorbidity in the warfarin users (Paper I).  
The interplay between ICH volume and GCS score is important for the interpretation 
of data concerning their impact on short term outcome. Both are well established 
prognostic factors for early mortality [81, 164-166].  In the present study ICH volume 
was not independently associated with 30-day mortality in multivariate analysis when 
GCS score was in the model, but highly significant when GCS was removed from the 
model (Paper II). ICH volume is the more causative of the two. Increasing ICH 
volume correlated significantly with a lower GCS score. 
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5.2.7 Factors associated with long term mortality (Paper II) 
For long term mortality in 30-day survivors we identified CHD, GCS score, and LA 
score as independent prognostic factors.  
The prognostic impact of LA is discussed separately below. 
The finding that CHD was associated with long term mortality in 30-day survivors 
contributes to an overall interpretation that mortality after survival of the acute phase 
greatly relates to the burden of vascular disease.   
Warfarin had no independent impact on long term mortality in 30-day survivors. This 
is in agreement with a report from Finland [155]. In a large study from the United 
States warfarin was associated with increased long term mortality. A likely 
explanation (suggested in Paper II) is that this may have been driven by an excess 
early mortality in warfarin users since all patients were assessed, not only 30-day 
survivors [78]. This seems more plausible than an independent long term effect after 
the acute phase. 
5.2.8 Leukoaraiosis   -  prognostic impact on mortality (Paper II) 
An important finding in this unselected Caucasian cohort is that LA is independently 
associated with both 30-day mortality and long term mortality in those who survive 
the first 30 days. Only two prior studies, both from South Korea and both in younger 
and more selected patients had reported on this association  [87, 88].    
Almost simultaneously with the publication of Paper II a study of 95 patients with 
ICH in the United States which supports our findings was published. It showed an 
association between increasing LA score on MRI and being dependent or dead at 14 
days and 3 months in univariate analysis and 3 months in multivariate analysis [167]. 
The patients were more selected than ours.  Since the study was MRI based and 
imaging was performed 1.8 days after symptom onset, only 95 of 196 consecutive 
patients were included. Patients were younger than ours (mean age 63.9±13.5 years 
versus 75.3 ±12). Only 6% used warfarin compared to 26.9% in our study. 38% of 
the patients were white compared to 97.8% in our study. The study did not report 
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long term results. Neither the American nor our study showed an association between 
LA and ICH volume. 
As of April 2013 the present study is still the only European study on the association 
between LA and ICH outcome, the only study on Caucasians, the only study on an 
unselected cohort and one of only two studies with long term data. With contribution 
from the present study the amount of data supporting the prognostic impact of LA has 
increased.  
5.2.9 Sex – not associated with mortality 
Sex was not associated with mortality, neither 30-day nor long term mortality.  For 
30-day mortality this is in general agreement with the literature, illustrated for 
instance by its absence  in the various published prognostic tools [82].  For long term 
mortality data are more conflicting with some studies showing  a higher risk in men 
[19, 83], one study a higher risk in women [84] and several showing no associations 
[11, 78, 80]. 
5.2.10 Recurrent ICH (Paper II) 
Our rate of recurrent ICH was in the low range compared with the literature. 
Importantly the number of recurrent ICH in our study was very low, only four cases. 
The findings must therefore be interpreted with great caution. When looking at only 
lobar index ICH in our study, recurrent ICH was seen in 4 of 36 cases (11.1%) over 
4.7 years. In a systematic review the overall rate of recurrent ICH was 2.3% per year 
and 4.4% for the subset with a lobar index ICH [94].  Notably 5 European studies 
were included, 4 of which were smaller than ours.  
Recurrent ICH was associated with lobar index ICH. This is in line with a common 
opinion and the AHA/ASA guidelines [1] which refer to a review and a cohort study 
in the United States [94, 168].  In Japan  no association was found between ICH 
location and the risk of recurrent ICH [96]. It has been suggested that these 
differences may be related to epidemiological differences between Asian and Caucasian 
populations [75].  However there are also recent studies from Sweden and Finland, 
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both larger than ours, that did not show a higher risk of recurrent ICH after lobar than 
deep cerebral index ICH [19, 97].  
A speculation is that differences in secondary prevention may contribute to the 
inconsistent results. The aggressiveness in blood pressure control and the threshold 
for antithrombotic treatment after ICH may vary. The impact of these treatment 
strategies on recurrence could in theory be different in patients with deep cerebral and 
lobar index ICH. Rigorous blood pressure control could for instance prevent 
recurrence more effectively after a hypertension related deep cerebral ICH than after 
a CAA associated lobar ICH.
5.2.11 Functional dependency (Paper III) 
At long term follow up after a median of 3.8 years 82% of the survivors lived in their 
private homes with or without assistance from the public home nursing service. No 
data for comparison exist. Two thirds were functionally independent with mRS 0-2. 
The only data for  comparison are from Finland in the 1980`s showing a  
corresponding proportion of 51% [91]. We found that mean age was lower in men 
than women amongst long term survivors as it was in the full cohort at baseline. 
Functional dependency expressed as mRS 3-5 was associated with LA. This is a 
novel finding in survivors of ICH. In ischemic stroke prior studies have shown a link 
between LA and a higher mRS [85, 169]. This association has been shown to be 
independent of the infarct volume [85]. In agreement with this the present study 
showed that LA was, but ICH volume was not associated with dependency.  Hence 
new findings in the current study regarding ICH fits with prior knowledge from 
ischemic stroke  supporting an association between LA and outcome caused by 
dysfunction in areas other than the acute injury. In a recent review the author 
concludes that in ischemic stroke LA affects outcome after multivariable adjustment 
for other patient characteristics and infarct volume. The author also concludes that 
further studies are needed on the mechanisms and to determine whether 
neurorehabilitation strategies need to take LA into account [51]. 
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Functional dependency was associated with female sex.  The reason for this is not 
clear. It is a novel finding and needs confirming from other studies before 
conclusions can be drawn. One can speculate that older women have a lower physical 
capacity and or less assistance in their immediate surroundings causing a more 
frequent shift towards dependency after an ICH. But first of all the finding should 
draw attention to the possibility of an excess dependency in female long term 
survivors and  encourage further studies on this topic.   
5.2.12 Cognitive impairment (Paper III) 
Cognitive impairment on the MoCA was a very frequent finding in the long term 
survivors. Lobar ICH location was independently associated with cognitive 
impairment. This has not been shown before. The cutoff for cognitive impairment of 
MoCA ≤23 was chosen to give priority to specificity. As expected the proportion 
with cognitive impairment was higher when the original cut off of MoCA≤25 was 
used. However the factors independently associated with the odds for having 
cognitive impairment did not change. 
The study does not discriminate cognitive impairment caused by the ICH from pre-
ICH impairment or evolving impairment after the ICH that relates to other 
pathologies. However the observations that the median ICH volume was relatively 
small (8.5 ml) and that ICH volume was not associated with cognitive impairment  
suggest that the cognitive impairment to some degree is independent of the acute 
ICH. It has been shown that vascular risk factors are associated with the progression 
from mild cognitive impairment to dementia [170-172] and that treatment of vascular 
risk factors is associated with reduced or delayed conversion to dementia [172, 173].  
Recognition of mild cognitive impairment is therefore very important. The present 
study contributes to increased awareness of this important issue.  A practical 
implication is that a rigorous blood pressure control may be at least as important after 
lobar as after deep cerebral ICH and not just for the prevention of recurrent stroke, 
but for the prevention of progressive loss of function including cognitive function.   
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5.2.13 Late seizures (not published) 
Late seizures in long term survivors were associated with lobar ICH location and also 
with greater ICH volume. The association with lobar location is well known for early 
seizures [99, 100], but prior to ours we found no studies showing this for late 
seizures. However findings in a study from France published online in may 2013 
showed several similarities with ours. From 325 patients with ICH 10% developed late 
seizures. The only independent prognostic factor was cortical involvement of the 
hemorrhage. Seizures were associated with a larger ICH volume in univariate 
analysis (Table 1 in their report); a point not commented on by the authors. Late 
seizures were not related to the occurrence of early seizures. Lobar microbleeds on 
MRI were associated with late seizures after adjustment for age, sex and cortical 
involvement of ICH. The authors suggested CAA as an underlying cause [174].  
Since late seizures in our study were associated with greater ICH volumes an intuitive 
mechanism is that a larger tissue injury predisposes for later seizures. An alternative 
speculation is that an underlying pathology such as CAA could increase the 
vulnerability both to the evolution of larger hematomas and to the evolution of 
epileptic foci which might not necessarily be restricted to the site of injury from the 
ICH. Other recent studies support that CAA can be an underlying cause of seizures; 
In Alzheimer’s disease a subset of patients experience unprovoked seizures [175] and 
in transgenic mice accumulation of β-amyloid in the brain can causes epilepsy [176].  
Patients who suffer a lobar ICH have a substantial risk of experiencing seizures and 
the risk persists even if no seizure has occurred at one year follow up. 
5.2.14 Lobar ICH – the burden hidden beneath  
Lobar ICH location was associated with increased risk of recurrent ICH (Paper II), 
cognitive impairment (Paper III) and late seizures (not published). Based on findings 
in this thesis it seems justified to speculate that lobar ICH may appear as a marker of 
an underlying cerebral pathology with an increased risk of several serious clinical 
manifestations. A lobar ICH may be a “tip of the iceberg”. In clinical routine the 
patient with an acute lobar ICH may be a patient with a progressive cerebral 
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condition with an increased risk of several important clinical manifestations. As 
discussed the underlying pathology could be CAA. 
5.2.15 Implications for secondary prevention 
This thesis suggests that a thorough diagnostic work up of patients with ICH 
including detailed imaging studies for evidence of vasculopathy yields a potential for 
improved assessment and handling of the individual risk profile.  A thorough work up 
of patients with an ICH should include a screening for cognitive impairment with a 
recommended tool such as the MoCA. 
Patients who suffer an ICH, in particular a lobar ICH have a high risk of having or 
developing cognitive impairment. This knowledge further strengthens the reasons for 
optimizing primary and secondary prevention focusing on both live style 
interventions and medication. 
Findings in this thesis suggest that rigorous blood pressure control may be at least as 
important after a lobar as after a deep cerebral ICH. The target for blood pressure 
control has traditionally been the prevention of subsequent strokes and death.  This 
thesis suggests that attention also should be given to the high rate of cognitive 
impairment and that more knowledge is needed about the possibility that optimized 
blood pressure control after an ICH could contribute to delaying or preventing overt 
dementia. Although no prospective studies of stroke survivors have explored the long 
term benefit of blood pressure control with dementia as the primary end point [177] 
evidence from studies of hypertension strongly suggests a treatment benefit. In a 
review of randomized trials of treatment of hypertension in which dementia was an 
included outcome measure the author concludes that “treatment of hypertension is an 
effective way to prevent dementia” [178].  
Evidence also exists for preventive effects of non pharmaceutical measures on 
cognition. In a recent review of studies evaluating the preventive effect of physical 
activity on vascular dementia the authors conclude that there is evidence supporting 
the beneficial effect and that  physical activity should be highlighted as part of 
secondary prevention in people at risk for cerebrovascular disease [179]. 
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Whether to (re-)start oral anticoagulation or platelet inhibitors in patients who have 
had an ICH demands cautious individual consideration. There is limited evidence to 
guide decisions. For platelet inhibitors it has been suggested that it may be relatively 
safe and justified in patients with risk factors for thromboembolic events [168]. The 
recommendations in the AHA/ASA guidelines are; “After a lobar ICH avoidance of 
anticoagulation is probably recommended, anticoagulation after nonlobar ICH and 
antiplatelet therapy after all ICH might be considered, particularly when there are 
definite indications for these agents” [1]. 
This study supports that after lobar ICH the risk of recurrent ICH is increased and 
special caution needed when considering the balance between potential benefit and 
risk for the individual patient. Improved MRI detection of CAA in clinical routine 
may possibly also contribute improved individual risk stratification.   
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6. Conclusions 
The incidence of first ever ICH in Southern Norway is in the mid range in Europe, 
and lower than in the only prior Norwegian incidence study in the mid nineteen 
nineties.  Men are at higher risk than women. Deep cerebral ICH is somewhat more 
common than lobar ICH.   
The proportion with OAT-ICH in Southern Norway is higher than in most reports 
reflecting a well implemented use of warfarin in atrial fibrillation in the elderly. Most 
cases of OAT-ICH occur with an INR in the therapeutic level. The mortality of OAT-
ICH is very high.  
The proportion of patients admitted to hospital within three hours of symptom 
duration was higher than the corresponding proportion in ischemic stroke.  
LA is independently associated with both short and long term mortality in unselected 
Caucasians with a first ever ICH. Long term mortality is also associated with CHD.  
The majority of long term survivors live in their private homes with or without 
assistance from the public home nursing system. Two thirds are functionally 
independent.  Dependency is associated with LA and female sex.  
Cognitive impairment is very common in long term survivors of ICH and associated 
with lobar ICH location. 
Recurrent ICH and late seizures were more frequent after lobar than non lobar ICH. 
Late seizures were associated with larger ICH volumes. 
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7. Clinical implications and future perspectives 
The mortality of ICH is high. Improvements in the prevention and treatment of ICH 
are strongly needed.  
OAT-ICH accounts for a large proportion of ICH and carries a particularly high 
mortality. Efforts to reduce the occurrence of OAT-ICH and improve the prognosis 
are needed.   
The well known crucial impact of the hematoma volume on outcome was seen clearly 
in this study. Hematoma volume will probably be the main target for future acute 
treatments. Efforts to combat the initial hematoma growth as early as possible are 
needed, preferably starting in the pre-hospital phase.  
This study suggests that a large proportion of patients with ICH arrive at hospital 
within three hours of symptom duration. This means that a large proportion may be 
eligible for and potentially benefit from new acute treatments of ICH. 
A thorough clinical and radiological work-up after an ICH is important for the 
individual risk factor assessment and handling. This thesis has shown that LA, readily 
assessable on non contrast baseline CT scans, is independently associated with short 
and long term mortality and with functional dependency in long term survivors. In the 
future the radiological work-up should preferably include studies of underlying 
vasculopathies, specifically CAA. Findings in this thesis support the speculation that 
an underlying vasculopathy, probably CAA  may be interrelated with Lobar ICH, 
cognitive impairment, recurrent ICH, and possibly also late seizures after ICH.   
Clinical work up after an ICH should preferably include a screening for cognitive 
impairment with a recommended tool such as the MoCA or an equivalent. Cognitive 
impairment should have increased attention in both clinical practice and research and 
gain recognition in our striving to reduce the burden of cerebrovascular disease. 
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9. List of errors 
The following errors have been found in the thesis: 
 
Paper I 
Paper contains two incorrect citations discovered after publication. Neither affects 
findings or conclusions. 
1. “In Norway published incidence data are limited to one study of stroke 
epidemiology in mid-Norway in 1994–1996 with only 55 cases of ICH”. The 
correct number in the reference is 45 not 55 cases [13]. 
2. “In the Swedish study neither bleeding in tumor nor recurrent incidents were 
excluded”. This is incorrect. Such cases were included in the study but 
excluded from calculation of the incidence [61]. 
 
Paper II 
 
Paper III 
 
Arnstein Tveiten August 2013 
  
